Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (50656)	1/12/2019 6:52:12 PM
From: tuck	Respond to of 52153

Wrt to the NDA, an expiration beyond what is available allows for possible regulatory slippage due to shutdown. Does that concern you at all? Can you refresh our memory on the guidance for the timing of the MACE data release and the DMD results? My memory - which is worse than usual these days - says April for MACE, but I was looking for another month or two cushion. If these are indeed well prior to June expiration, I'm a little puzzled by the implied volatilities I'm seeing. They're elevated, but not that much by biotech standards. TIA & Cheers Tuck

To: Biomaven who wrote (50656)	1/12/2019 8:08:41 PM
From: tuck	Read Replies (1) \| Respond to of 52153

So I double checked with their January 2019 corporate presentation, which is the latest public statement they've made that I'm aware of, and it says MACE data in the first half of this year. That's a couple of weeks beyond June expiration. I see the DMD data is expected this quarter. I haven't researched the DMD aspect yet, and I guess I should, to shape my strategy (I have a fair sized core position I don't expect to sell). To hedge or not to hedge during this time frame? Having gone over the MACE issue with you - thanks again for your feedback - I want to be long for that. Cheers, Tuck